Antigenics reports positive Ph III follow-up data on Oncophage

USA-based Antigenics has reported encouraging additional follow-up data from a Phase III trial of its investigational therapeutic cancer vaccine Oncophage (vitespen). The end-of-study results, which reflect an additional 17 months' data collection, showed that, in a substantial subset of patients (n=362) at intermediate risk for disease recurrence, Oncophage demonstrated a clinically-significant improvement in recurrence-free survival of approximately 45% (p<0.01). In addition, updated analysis in this group of patients revealed a new potential benefit: for intermediate-risk Oncophage patients there was a trend towards improved overall survival, the study's secondary endpoint.